Videos and Articles

From the Medscape Physician Destination:
Individualizing RA Management for Optimal Long-term Outcomes

Although rheumatoid arthritis (RA) is a chronic, progressive disease,its precise course varies widely among patients. Accurate assessment and frequent monitoring of disease status beyond symptomatic complaints can help to guide the selection of optimal treatment and improve long-term prognosis for individual patients.


Kathryn Hobbs, MDLong-term considerations in the management of RA

Could your patients with RA be experiencing
more structural damage than you think?

Kathryn Hobbs, MD, is Scientific Director of the Clinical Research Unit at the Denver Arthritis Clinic in Denver, Colorado. In this short slide presentation, Dr. Hobbs discusses the importance of frequent assessment of RA disease activity.


Biomarkers and the biology of RA: relevance for clinical practice

A multiplexed biomarker panel could be used to assess RA disease activity, individualize treatment, and improve long-term patient outcomes.

William Robinson, MD, is Assistant Professor of Medicine in the Division of Immunology and Rheumatology at the Stanford University School of Medicine in Palo Alto, California. In this short interview, Dr. Robinson discusses how biomarkers may soon be incorporated into day-to-day clinical practice.


Stephen A. Paget, MD, FACP, FACR Getting the complete picture: effective assessment of patients with RA

Disease activity, structural damage, and functional status are the 3 pillars of RA assessment and management. What are the most effective ways in which to assess these criteria over time?

Stephen A. Paget, MD, FACP, FACR, is Physician-in-Chief and Chairman of the Division of Rheumatology at the Hospital for Special Surgery, and the Joseph P. Routh Professor of Medicine and Rheumatic Diseases at the Weill Medical College of Cornell University and the New York Presbyterian Hospital, all located in New York City. In this expert Q&A, Dr. Paget provides insight into monitoring RA disease activity and individualizing treatment.

Selected References Supporting Crescendo’s Vision and Mission

Note: These are provided for background only and are not intended to suggest claims about the accuracy or reliability of any Crescendo tests.

Tight Control

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active Rheumatoid Arthritis. Ann Rheum Dis. 2009 Jan 20. Epub ahead of print.

Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet. 2004;364(9430):263-9.

Sokka T, Mäkinen H, Puolakka K, et al. Remission as the treatment goal — the FIN-RACo trial. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S-74-6.

Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443-9. Epub 2007 May 22.

Quantitative Biology

Alex P, Szodoray P, Knowlton N, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(4):584-92.

Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537-45.

Centola M, Frank MB, Bolstad AI, et al. Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: a potential breakthrough diagnostic and individualized therapy-design tool. Scand J Immunol. 2006;64(3):236-42.

Emery P, Gabay C, Kraan M, et al. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int. 2007;27(9):793-806. Epub 2007 May 16.

Saad F. Optimizing patient therapy: the role of bone markers? Cancer Treat Rev. 2006;32 Suppl 1:3-6.

Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford). 2007;46(3):417-25. Epub 2006 Aug 27.

Szodoray P, Alex P, Frank MB, et al. A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(12):1466-76. Epub 2006 Apr 25.

Robust Assay Development

He YD, Dai H, Schadt EE, et al. Microarray standard data set and figures of merit for comparing data processing methods and experiment designs. Bioinformatics. 2003;19(8):956-65.

Simon R. Development and validation of biomarker classifiers for treatment selection. J Stat Plan Inference. 2008;138(2):308-320.